Skip to main content
Premium Trial:

Request an Annual Quote

Sloan-Kettering to Adopt Genomatix Gene-Regulation Software

NEW YORK, Nov. 30 (GenomeWeb News) - The Memorial Sloan-Kettering Cancer Center in New York has signed an agreement with German informatics firm Genomatix to use its GenomatixSuite database and analysis tool for gene-regulatory networks, Genomatix said today.


Under the terms of the agreement, Munich-based Genomatix will provide all MSKCC clinical and research staff, fellows, and students with full access to GenomatixSuite. MSKCC's bioinformatics core facility will coordinate the access, Genomatix said in a statement.


GenomatixSuite also contains the largest available database of real mammalian promoter DNA sequences, the company said.


Genomatix said it hopes to eventually expand the agreement to all researchers at the Rockefeller University and Cornell Weill Medical College, academic institutions with which MSKCC is affiliated.


Financial terms of the deal were not disclosed.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.